Scrip: industry news and insights
Cantargia Confident About Nadunolimab’s Prospects For Pancreatic Cancer
By Kevin Grogan 29 Jun 2022
The selection of nadulonimab by the Pancreatic Cancer Action Network for its adaptive clinical trial is a strong validation of...